Healthcare
JW (Cayman) Therapeutics Co. Ltd(JWCTF)
Live Price
Offline$0.2375
+0.00% today
1Y Change
-5.00%
Window
Jun 26, 2025 → Jun 23, 2026
- Market Cap
- $840.00M
- Revenue Growth
- +74.7%
- EPS Growth
- +7.0%
- Dividend Yield
- 0.0%
Coverage: 255 bars · Jun 26, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
JW (Cayman) Therapeutics Co. Ltd (JWCTF) is a Healthcare stock with a market cap of $840.00M and listed on OTC. The stock last traded around $0.24 and down 5.0% across the available one-year price window (Jun 26, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +74.7%, EPS growth of +7.0%, a dividend yield of 0.0%. What stands out right now is revenue +74.7%, EPS +7.0%, free cash flow 0.0% with operating margin -105.5% and ROIC -36.1%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines JWCTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+74.7% vs +7.6% peer median
Operating Margin
Below sector median
-105.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +74.7% and EPS at +7.0%, with operating margin around -105.5%.
Benchmark Edge
JWCTF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JWCTF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JWCTF Max Drawdown
-64.03%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JWCTF and SPY.
Company Overview
JW (Cayman) Therapeutics Co. Ltd
Other OTC
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
- Leadership
- Min Liu
- IPO Date
- Jul 15, 2021
- Employees
- 281
- Street Address
- Building B
- Mailing
- Shanghai
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 400 820 0033
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 3.0
- Price/Book
- 1.5
Growth
- Revenue
- +74.7%
- EPS
- +7.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 43.1%
- Operating Margin
- -105.5%
- Net Margin
- -196.1%
- ROE
- -75.1%
- ROIC
- -36.1%
Balance Sheet
- Debt/Equity
- 0.47
- Current Ratio
- 1.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.